M edicare beneficiaries are typically seen by multiple providers for acute and chronic care, 1 particularly specialists who provide time-limited consultation on newly diagnosed conditions or acute exacerbations of existing conditions. 2 Primary care physicians may also engage specialists to comanage the complex care of beneficiaries on an ongoing basis, because a majority of beneficiaries have multiple chronic conditions (MCCs). Clinically appropriate referrals to multiple specialists may compromise the continuity of care for beneficiaries and create care plans that patients may find challenging to reconcile, 3, 4 unless specialists proactively coordinate care or repatriate patients back to the primary care provider who initiated the referral. 5 In numerous studies, more continuous care (measured as a higher concentration of outpatient visits with fewer providers) has been associated with lower hospital admission rates and lower health expenditures. [6] [7] [8] [9] [10] Having fewer prescribers (as opposed to providers) has also been associated with lower rates of hospital admission and emergency department visits in a cohort of Veterans 11 and with lower rates of medication utilization. [12] [13] [14] [15] [16] [17] In a study of 1400 adults aged 17 and older from the Third National Health and Nutrition Examination Survey collected in 1988-1991, patients who had a usual provider of care or usual site of care had better glycemic control than patients with no usual source. 18 A second study of 256 community health center patients in Texas found that better continuity of care was associated with better diabetes control. 19 Results from these studies would suggest that continuous care improves disease control in non-Medicare cohorts and reduces emergent care needs, which together may reduce patients' need to seek emergency department and inpatient care.
No prior study has examined the association between continuity of care and disease control in Medicare fee-forservice (FFS) beneficiaries, because lab values have not previously been available and the prior studies examining care continuity and disease control were on non-Medicare community-based samples. The measure of continuity examined here-number of prescribers of cardiometabolic medications-is different from continuity measures considered in prior studies in three ways. First, it is based on the subset of providers who prescribe medications instead of providers seen during outpatient visits regardless of having prescribed medications. Second, this prescriber measure is disease-specific by only considering prescribers of cardiometabolic medications instead of all-cause outpatient visits for any reason. Third, the number of prescribers is examined as a simple count instead of an index as most care continuity measures are constructed. This continuity measure has been associated with an important predictor of disease control (medication refill adherence) in prior studies of Veterans and Medicaid patients. 16, 17 
METHODS

Data and Participants
In this retrospective cohort study, we used 2010-2011 Beneficiary Summary Files (BSF) and Medicare Part D files for all Medicare FFS beneficiaries living in 10 east coast states (NY, NJ, MD, DE, VA, NC, SC, GA, FL, and AL). Demographic characteristics were identified from the BSF and comorbid conditions were obtained from the BSF's Chronic Condition Warehouse (CCW) segment. The CCW segment identifies 27 chronic conditions as far back as 1999, based on standardized algorithms that draw from inpatient and outpatient Medicare claims. 20 The 2010-2011 Part D Prescription Drug Event files were used to identify which beneficiaries were taking oral medications to manage diabetes or dyslipidemia (see Appendix A, Supplemental Digital Content 1, http://links.lww.com/MLR/B292 for list of medications), and the 2010 Prescriber Characteristics File (PCF) was used to identify the count and specialty of prescribers of oral cardiometabolic medications. The disease control outcomes were obtained from 2011 laboratory results data from a large national vendor with significant market share in the 10 states under investigation. 21 MCC beneficiaries in this study were 65-80 years old on . Finally, beneficiaries included for analysis had glycemic or lipid testing in 2011 with matching lab results data and had >90 days of cardiometabolic medications in 2010 from prescribers whose specialty could be determined from the Part D PCF. Lab results were matched to Medicare data on individual beneficiaries based on a patient identifier that was available in both datasets. The requirement to have matching lab results data resulted in a 48% sample reduction in the diabetes cohort and a 47% reduction in the dyslipidemia cohort. Beneficiaries were excluded either because they did not have a lab test in 2011 or they had a lab test that was processed by different laboratory vendor. We excluded beneficiaries with end-stage renal disease due to differences in patterns of MCC care management and beneficiaries with hypertension because we lacked blood pressure control data.
The final analytic cohort included 51,879 beneficiaries with diagnosed diabetes and 129,762 beneficiaries with diagnosed dyslipidemia, which were the fifth most prevalent (28%) and second most prevalent (45%) conditions in 2010, respectively. 22 Beneficiaries with diabetes but no lab data were significantly different in most characteristics from beneficiaries with lab data, including being slightly older, taking more medications and having a higher prevalence of most chronic conditions (Appendix D, Supplemental Digital Content 1, http://links.lww.com/MLR/B292). Similarly, beneficiaries with dyslipidemia but no lab data were significantly different from beneficiaries with lab data.
Outcome and Explanatory Variable of Interest
In the diabetes cohort, the binary outcome of glycemic control was constructed from the last available glycated hemoglobin (HbA1c) in 2011 laboratory results data. Glycemic control was defined as having an HbA1c < 7.5 based on clinical guidelines for this age group. 23 In the dyslipidemia cohort, the binary outcome of lipid control was constructed from the same laboratory results data. Lipid control was defined as an low-density lipoprotein < 100 for beneficiaries with heart disease or diabetes or an low-density lipoprotein < 130 for all other beneficiaries. 23 We examined diabetes control because poor glycemic control puts beneficiaries with type 1 diabetes at risk for developing retinopathy, nephropathy, neuropathy and heart disease, 24 and puts beneficiaries with type 2 diabetes at risk for retinopathy and nephropathy. 25 We examined lipid control because poor lipid control puts beneficiaries with dyslipidemia at risk for heart disease, myocardial infarction and stroke. 26 The explanatory variables of interest were the total number of all prescribers of medications to manage diabetes, hypertension or dyslipidemia, which was constructed by linking the 2010 PCF to the 2010 Prescription Drug Event data through CCW Prescriber identifiers. In contrast to prior studies that used continuity indices to reflect concentration of visits among providers, 6, 7 we constructed a prescriber count based on the total number of unique prescribers who wrote a prescription for a filled (or refilled) cardiometabolic medication without regard for prescriber specialty. This prescriber continuity measure has face validity, includes prescribers involved in the clinic management of these conditions of interest, and does not require exclusion of beneficiaries with too few visits to calculate the index. 7 These 2010 prescriber variables were lagged by 1 year from the 2011 disease control outcome to reduce simultaneity bias.
Data Analysis
We generated means and standard deviations for continuous variables, proportions of binary variables, and bivariate associations between control of glycemia or lipids and the number of prescribers. For each cohort, logistic regression of well-controlled disease in 2011 was estimated as a function of a categorical nonspecific prescriber variable (2 prescribers, 3 prescribers, 4 prescribers, 5+ prescribers) in 2010 with 1 prescriber serving as the reference group and other covariates. The prescriber variable was lagged 1 year from the disease control outcome to reduce the reverse causality that could arise by modeling these variables and outcomes in the same year.
All regressions adjusted for age, sex, race, Medicaid enrollment, 17 chronic conditions available from the BSF's Chronic Condition segment, the number of all medications filled in 2010 and state-fixed effects. The chronic conditions included hypothyroidism, atrial fibrillation, anemia, asthma, benign prostatic hyperplasia, cancer (as a combination of indicators for breast, colorectal, prostate, lung, and endometrial cancer), chronic kidney disease, chronic obstructive pulmonary disease, dementia/Alzheimer's disease/related conditions, depression, heart failure, ischemic heart disease, osteoporosis, rheumatoid arthritis/osteoarthritis, and stroke. This study was approved by the Institutional Review Board of the Duke University Health System.
RESULTS
Patient Characteristics and Diabetes Control by Number of Prescribers
In the diabetes cohort, the average age was 72.5, a majority (56%) was female, 74% were white race, 17.7% were dually enrolled in Medicaid and 80% had comorbid dyslipidemia. The average beneficiary took 11.7 medications for all conditions and had 1.8 prescribers of cardiometabolic medications ( Table 1 ). The proportion of Medicare beneficiaries with well-controlled diabetes in 2011 was 76% for beneficiaries with one prescriber, which decreased to 65% for beneficiaries with 5+ prescribers (Fig. 1) .
In adjusted analyses (Table 2) , beneficiaries with diabetes and multiple prescribers had lower odds of having glycemic control than beneficiaries with a single prescriber 
Patient Characteristics and Lipid Control by Number of Prescribers
In the dyslipidemia cohort, the average age was 72.5, a majority (58%) was female, 84% were white race, 12% were dually enrolled in Medicaid and 42% had comorbid diabetes. The average beneficiary took 10.1 medications for all conditions and had 1.6 prescribers of cardiometabolic medications. The unadjusted proportion of Medicare beneficiaries with well-controlled dyslipidemia in 2011 was similar (91-92%) across the number of prescribers (Fig. 1) . In adjusted analysis (Table 2) , beneficiaries with dyslipidemia and 3 prescribers had lower odds of having lipid control than beneficiaries with a single prescriber (OR = 0.92; 95% CI, 0.86-0.99).
Beneficiaries had lower odds of having glycemic control if they had comorbid congestive heart failure (OR = 0.90; 95% CI, 0.84-0.96), dementia, Alzheimer's or related disorders (OR = 0.87; 95% CI, 0.80-0.95), depression (OR = 0.75; 95% CI, 0.71-0.80) or rheumatoid arthritis/osteoarthritis (OR = 0.95; 95% CI, 0.91-0.99). Older beneficiaries had higher odds of glycemic control than beneficiaries aged 65-69 (age 70-74: OR = 1.08; 95% CI, 1.03-1.13; age 75+: OR = 1.24; 95% CI, 1.18-1.30). Beneficiaries also had higher odds of glycemic control if they had diabetes, (OR = 1.51; 95% CI, 1.44-1.57), hypertension (OR = 1.20; 95% CI, 1.14-1.26), atrial fibrillation (OR = 1.37; 95% CI, 1.25-1.49), ischemic heart disease (OR = 1.21; 95% CI, 1.16-1.27) or osteoporosis (OR = 1.10; 95% CI, 1.03-1.18).
DISCUSSION
The impact of care continuity on health care utilization and expenditures of Medicare beneficiaries has been examined in prior work, 6 but no prior studies have examined the impact of the number of prescribers on disease control in this population. To our knowledge, this is the first study to examine the association between the number of prescribers and disease control for Medicare FFS beneficiaries with diabetes or dyslipidemia. The role of care continuity in control of chronic conditions is important to understand, since poorly controlled disease puts MCC beneficiaries at risk for adverse events that lead to emergency department visits and hospitalizations. 27 Care discontinuity experienced by MCC beneficiaries may partly explain why they have more hospital visits, more physician office visits and higher Medicare expenditures than beneficiaries with 0-1 conditions. 28,29 MCC beneficiaries may also be at greater risk of being prescribed drugs with harmful interactions than other beneficiaries due to their complex medication regimens. 30, 31 In the cohort of beneficiaries with diabetes, multiple prescribers were associated with worse glycemic control. The significant results are consistent with 2 prior studies in which better continuity of care was associated with better glycemic control, which were based on much smaller, nonMedicare samples and data that was collected 15-20 years before the 2011 data used in this study. 18, 19 Beneficiaries with dyslipidemia and 3 prescribers had modestly worse lipid control than beneficiaries with single prescriber. Having 2 prescribers or 4 or more prescribers was not associated with lipid control. It is possible that the number of prescribers was associated with glycemic control but not lipid control, because diabetes regimens often involve polypharmacy, whereas lipid-lowering regimens are more straightforward by often requiring only a single statin. The diabetes cohort results were farther from the null than the lipid cohort results, but future research that accounts for the extent of patients' polypharmacy is needed to reexamine these associations.
There are at least two explanations for the diabetes findings. First, seeing multiple prescribers could adversely impact disease control by nonadherence to medications or lifestyle change recommendations. In separate analyses of this cohort, we found a null association between availability of oral diabetes medications and number of prescribers, (Maciejewski et al, unpublished data) which suggests that the medication nonadherence pathway to disease control may not be an important factor. It is possible that patients with Adherence = 1 if continuous PDC > 80%; = 0 otherwise; fixed effects for the 10 states were also included with Florida as the reference state. Diabetes control = 1 if HbA1c < 7.5. Lipid control = 1 if low-density lipoprotein < 100 for beneficiaries with heart disease or diabetes or an low-density lipoprotein < 130 for all other beneficiaries. multiple prescribers have worse disease control due to nonadherence to lifestyle recommendations. However, we did not have data on provider recommendations or patient behavior to be able to evaluate this lifestyle pathway. The second possible explanation is unobserved confounding of disease severity drives these results, such that beneficiaries with more severe diabetes are simply referred to more providers, some of whom prescribe medications. We did not have data to control for disease severity at baseline, unobserved confounding is plausible and is a limitation of this study. Future work that captures these unobservable factors would elucidate the underlying mechanisms to inform improvements to providers' management of MCC patients. There are additional limitations that must be acknowledged. These results may not generalize beyond the Medicare FFS beneficiaries in these 10 states in 2010-2011, and may not generalize to beneficiaries who were excluded due to the lack of laboratory values. Older adults receiving care from integrated health systems with more information continuity due to connected electronic health records may have different results from those reported here. Further, clinical significance (especially for lipid results) is not implied by statistical significance. Finally, claims data lack information on geriatric conditions (eg, urinary incontinence, falls, dizziness, visual impairment) that commonly cooccur with the medical conditions measured. 32, 33 We unexpectedly found that female sex was positively associated with diabetes control but negatively associated with lipid control, the latter of which is consistent with prior sex comparisons in Medicare Advantage enrollees in 2004 34 and sex comparisons in the Multi-Ethnic Study of Atherosclerosis. 35 The positive association between female sex and diabetes control finding was inconsistent with results from these prior 2 studies, 34, 35 so merits reexamination in future research.
Over the course of their enrollment in the traditional FFS program, the care of many MCC beneficiaries becomes fragmented as they are referred to specialists with complementary expertise to address newly diagnosed conditions or acute exacerbations of existing conditions. Some specialists will repatriate a beneficiary back to the primary care provider 5 after addressing the issues that prompted referral, while other providers will decide to comanage a beneficiary with the primary care provider.
This study builds on prior care continuity studies on older adults because we examine continuity of medication management and its association with disease control, which may improve understanding of the association between continuity of care and health care utilization. This analysis was made possible by the linkage of laboratory results data to Medicare FFS claims, 21 which creates the opportunity to conduct patient safety and quality analyses that were not previously possible.
